Two FDA advisory committees — the Nonprescription Drugs Advisory Committee and the Reproductive and Urologic Drugs Advisory Committee — were initially scheduled to meet on Nov. 18, but the agency pushed back that date to "review additional information requested related to the Opill Rx-to-OTC switch," according to the company.ufabet987
top of page
bottom of page